Danielle Rapaccioli

Davis Polk advised Coloplast on its acquisition of Nine Continents Medical, an early stage company pioneering an implantable tibial nerve stimulation treatment for over-active bladder. The…

Davis Polk advised the representative of the initial purchasers of a Rule 144A/Regulation S offering by Acadia Healthcare Company, Inc. of $475 million aggregate principal amount of…

Davis Polk advised the representative of the several underwriters in connection with the $500 million secondary offering of 5,000,000 shares of common stock of Fiserv, Inc. by New Omaha…

Davis Polk advised the sales agent in connection with an SEC-registered at-the-market offering by InflaRx N.V. of its shares of common stock for up to an aggregate amount of $50…

Davis Polk advised Raízen Fuels Finance S.A., as issuer and Raízen Combustiveis S.A. and Raízen Energia S.A., as guarantors, in connection with Raízen Fuels’ $225 million reopening of its 5…

Davis Polk advised the representatives of the underwriters in connection with the $70 million follow-on public offering of 5,000,000 shares of common stock of TransMedics Group, Inc…

Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with a SEC-registered follow-on offering of 4,573,863 shares of common stock…

Davis Polk advised FedEx Corporation on its SEC-registered offering of $1 billion principal amount of 3.800% notes due 2025, $750 million principal amount of 4.250% notes due 2030 and $1.25…

Davis Polk advised PPL Capital Funding, Inc. on its registered offering of $1.0 billion aggregate principal amount of 4.125% senior notes due 2030, fully and unconditionally guaranteed by…

Davis Polk advised the sales agent on the SEC-registered at-the-market offering by Atara Biotherapeutics, Inc. of its common stock for up to an aggregate amount of $100 million. Based in…